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Abstract
Background: Vaginal infections are a risk factor for preterm delivery. In this study, we sought to evaluate the
vaginal flora of pregnant women receiving opioid maintenance therapy (OMT) in comparison to non-dependent,
non-maintained controls.
Methods: A total of 3763 women with singleton pregnancies who underwent routine screening for asymptomatic
vaginal infections between 10 + 0 and 16 + 0 gestational weeks were examined. Vaginal smears were Gram-stained,
and microscopically evaluated for bacterial vaginosis, candidiasis, and trichomoniasis. In a retrospective manner,
data of 132 women receiving OMT (cases) were matched for age, ethnicity, parity, education, previous preterm
delivery, and smoking status to the data of 3631 controls. The vaginal flora at antenatal screening served as the
primary outcome measure. Secondary outcome measures were gestational age and birth weight.
Results: In the OMT group, 62/132 (47 %) pregnant women received methadone, 39/132 (29.5 %) buprenorphine,
and 31/132 (23.5 %) slow-release oral morphine. Normal or intermediate flora was found in 72/132 OMT women
(54.5 %) and 2865/3631 controls [78.9 %; OR 0.49 (95 % CI, 0.33–0.71); p < 0.001]. Candidiasis occurred more frequently
in OMT women than in controls [OR 2.11 (95 % CI, 1.26–3.27); p < 0.001]. Findings were inconclusive regarding bacterial
vaginosis (± candidiasis) and trichomoniasis. Compared to infants of the control group, those of women with OMT had
a lower mean birth weight [MD −165.3 g (95 % CI, −283.6 to −46.9); p = 0.006].
Conclusions: Pregnant women with OMT are at risk for asymptomatic vaginal infections. As recurrent candidiasis is
associated with preterm delivery, the vulnerability of this patient population should lead to consequent antenatal
infection screening at early gestation.
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Background
Opioid dependence during pregnancy is a growing con-
cern, as one-third of the patients entering opioid mainten-
ance therapy (OMT) are women of childbearing age [1].
Oral methadone has been recommended as an OMT for
women with opioid dependence during pregnancy since
the 1970s and is still considered the standard treatment
for this patient population [2]. As an alternative with
proven safety and efficacy for pregnant women and their
foetuses, buprenorphine was introduced in the early 1990s
[3]. The rationale for OMT is to prevent complications of
illicit drug use and narcotic withdrawal, as well as to
encourage antenatal care and reduce criminal activity [2].
Despite multidisciplinary care, opioid-maintained pregnant
women still have an increased risk for adverse pregnancy
outcomes such as preterm delivery (PTD), abruption of the
placenta, foetal growth restriction, and intrauterine foetal
death [4].
In view of the fact that many women with opioid de-
pendence suffer from socioeconomic deprivation, with
frequent exposure to violent environments, physical and
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sexual abuse, the risk for vaginal infections should be
considered further [5]. This issue is of particular import-
ance, since vaginal infections at early gestation have
been shown to contribute to the multifactorial mecha-
nisms of PTD [6, 7]. Recently, our study group suggested
an improvement of obstetrical outcomes through routine
screening and consequent treatment for asymptomatic
vaginal infections in an overall population of pregnant
women at our tertiary referral centre [8].
In addition to the mental stability that is needed,
somatic factors should be considered during the ante-
natal care of pregnant women with OMT. However, no
population-based study has yet quantified the likelihood
of vaginal infections in these women, accounting for the
effect on pregnancy outcomes. Given the known impact
of vaginal infections and the possibility of an accumula-
tion of risk factors through OMT and vaginal infections,
we considered it a matter of particular interest to inves-
tigate the vaginal flora of opioid-maintained pregnant
women. Therefore, the present study aimed to stratify
the risk of vaginal infections in pregnant women with




We retrospectively analysed data from all women who
presented with singleton pregnancies at the Medical
University of Vienna, Department of Obstetrics and Gy-
naecology, between 1 January 2005 and 1 January 2015.
Our centre is specialised in high-risk pregnancy care
and serves about 3000 deliveries of publicly health-insured
women per year, including referrals from throughout
Central Eastern Europe. As part of our routine antenatal
service, all women who registered for a planned delivery
at our department underwent screening for asymptomatic
vaginal infections during a prenatal consultation between
10 + 0 (10 weeks plus 0 days) and 16 + 0 (16 weeks plus
0 days) gestational weeks. According to the official Austrian
welfare programme, further obstetric consultations were
performed at predetermined time points in obstetric offices
[9]. For opioid-dependent, opioid-maintained women, alter-
nating consultations were performed weekly up to daily at
the addiction clinic of the Medical University of Vienna. All
women were part of a comprehensive, multidisciplinary
treatment approach for the management of substance-
dependant pregnant women at our tertiary referral centre
[10]. Their treatment team consisted of medical doctors,
psychologists, nurses, and social workers, who closely col-
laborated with the Departments of Psychiatry and Psycho-
therapy, and Pediatrics and Adolescent Medicine, as well as
with other hospitals and relevant institutions (e.g., child
welfare services, criminal justice system, etc.).
Women on OMT received either a) methadone, b)
buprenorphine, or c) slow-release oral morphine (SROM)
during pregnancy. Treatment decisions, including OMT
choice, dosing, and frequency of visits were individualised
and determined by the patient and the treating physicians,
following evidence-based treatment recommendations [11].
Alcohol abuse was defined as the regular consumption of
alcohol-containing beverages during pregnancy; smoking
status was evaluated by the number of cigarettes, with both
obtained by questionnaires.
Procedure
In all women, vaginal smears were obtained by vaginal
fluid collection with sterile swabs from the lateral vaginal
wall and posterior fornix vaginae. Smears were Gram-
stained and microscopically analysed by one of four bio-
medical laboratory assistants, trained and experienced in
gynaecological cytopathology at a laboratory certified
according to DIN EN ISO 9001:2008. The protocol
involved classification of the vaginal flora as described
by Nugent et al. [12]. According to the scoring system, a
score of 0–3 was regarded as normal flora, 4–6 as inter-
mediate flora, and 7–10 as bacterial vaginosis (BV). In
addition, the presence or absence of Candida species
(spp.), Gardnerella and Trichomonas vaginalis (T. vagi-
nalis) was assessed using a microbial identification test
with DNA probe technology (BD Affirm™ VP III; Becton
Dickinson Co., Sparks, MD, USA). The test uses DNA
sequences that bind or hybridize only with the nucleic
acid of targeted organisms. The hybridization reaction is
highly sensitive and specific in the simultaneous detection
and identification of the three major causes of vaginitis. In
cases of normal or intermediate flora, women did not re-
ceive any treatment. The treatment of BV included clinda-
mycin 2 % vaginal cream for 6 days in cases of a primary
infection, oral clindamycin 0.3 g twice daily for 7 days in
cases of recurrent BV infection, local clotrimazole 0.1 g
for 6 days in cases of vaginal candidiasis, and local metro-
nidazole 0.5 g for 7 days in cases of trichomoniasis [13].
Antibiotic treatment was followed by vaginally applied
Lactobacillus spp. for 6 days to rebuild the physiological
flora [14].
Study groups
One hundred thirty-two consecutive pregnant women
who underwent routine antenatal infection screening were
identified for assignment to the OMT group based on
their participation in the treatment programme for
opioid-dependent women at the addiction clinic. Women
of the control group reported that they were neither tak-
ing drugs, nor receiving OMT, as evaluated by self-report.
There was no significant difference in gestational age at
vaginal screening between the study groups. Women who
were antenatally referred from other hospitals due to
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imminent PTD, as well as those who did not undergo the
antenatal screening programme, were not eligible for the
study. We conducted a matched-group analysis to assess
the impact of OMT and opioid dependence on the ob-
served outcome measures. Cases and controls were
matched according to the following parameters: maternal
age (years), ethnicity (Caucasian vs. non-Caucasian), parity
(primipara vs. multipara), previous PTD (yes vs. no), edu-
cational level (tertiary vs. non-tertiary), and smoking status
(smoking vs. non-smoking). These matching parameters
were selected due to their influence on PTD [15–17]. We
included only those combinations of the matching vari-
ables for which cases and controls were present.
Outcome measures
The vaginal flora at antenatal screening served as the
primary outcome variable, recorded as normal flora,
intermediate flora, or vaginal infection in cases of BV
and/or colonization with Candida spp. and/or T. vagi-
nalis. By definition, women with asymptomatic vaginal
infections did not have any signs of conspicuous redness,
discharge, or vaginal itch. The secondary outcome vari-
ables included gestational age at delivery and neonatal
birth weight. PTD was defined as spontaneous delivery
at or less than 36 + 6 gestational weeks (36 weeks plus
6 days) due to preterm premature rupture of the mem-
branes and/or preterm labour. Stillbirth was defined as
the term or preterm delivery of an infant who had died
in utero and was born with an Apgar score of 0/0/0.
Data were extracted from obstetric databases, patient
charts, and microbiologic reports.
Statistical analysis
Descriptive statistics were used to summarise demographic
information. Continuous data are given as mean ± standard
deviation (SD), unless stated otherwise. Discrete data are
presented as numbers (percentages). For continuous out-
comes, a linear mixed model was used, where maternal
opioid dependence was a fixed effect, and matched groups
were incorporated as a random intercept. Dichotomous
outcomes were analysed by means of a conditional logistic
regression model that adjusted for all potentially confoun-
ding factors. A two-sided p-value < 0.05 was considered
statistically significant. We accounted for multiplicity by
applying the Bonferroni correction to the resulting p-values
when appropriate. Patient charts were electronically
reviewed using PIA Fetal Database, version 5.6.16.917
(General Electric Company, GE Viewpoint, Munich,
Germany). Calculations were performed using R-Project
for Statistical Computing, version 3.1.3 (R Development
Core Team, MA, USA) and SPSS Statistics, version 23.0
(IBM, NY, USA). Figures were constructed using Microsoft
Excel, version 14.6.1 (Microsoft, WA, USA).
Results
A total of 3763 women with singleton pregnancies, who
underwent antenatal screening for asymptomatic vaginal
infections, were eligible for study inclusion. From this
group, we identified 132/3763 (3.5 %) women with OMT
(cases) and 3631/3763 (96.5 %) matched controls. In the
OMT group, 62/132 (47 %) women received methadone,
39/132 (29.5 %) buprenorphine, and 31/132 (23.5 %)
SROM. The mean daily doses of methadone, buprenor-
phine, and SROM at delivery were 57 ± 29 mg, 6 ± 5 mg,
and 410 ± 201 mg, respectively. Patient characteristics of
the study participants are shown in Table 1.
On antenatal screening smears, 60/132 (45.5 %) women
in the OMT group had an asymptomatic vaginal infection,
compared to 766/3631 (21.1 %) controls. The conditional
logistic regression model revealed a statistically significant
difference in the occurrence of asymptomatic vaginal in-
fections between the study groups [45.5 versus 21.1 %; OR
1.73 (95 % CI, 1.19 to 2.53); p = 0.004]. The prevalence of
pathogens in the vaginal flora is shown in Fig. 1. Rates of
Candida colonization were higher in the OMT group
compared to the control group [27.3 versus 12.9 %; OR
2.11 (95 % CI, 1.36 to 3.27); p < 0.001]. BV rates were also
higher in the OMT group compared to the control group,
but they were inconclusive as to whether or not a differ-
ence was present [18.2 versus 7.4 %; OR 1.53 (95 % CI,
0.93 to 2.53); p = 0.094]. No significant differences were
Table 1 Patient characteristics of the 3763 study participants
Variable OMT group Control group Total
Mean ± SD Mean ± SD Mean ± SD
N (%) N (%) N (%)
Participants 132/3763 (3.5) 3631/3763 (96.5) 3763/3763 (100)
Age at delivery
(years)
27.0 ± 4.3 30.4 ± 5.5 30.3 ± 5.5
Caucasian ethnicity 130/132 (98.5) 3588/3631 (98.8) 3718/3763 (98.8)
Parity
Primiparae 64/132 (48.5) 1186/3631 (32.7) 1250/3763 (33.2)
Multiparae 68/132 (51.5) 2445/3631 (67.3) 2513/3763 (66.8)
Previous PTD 3/68 (4.4) 122/2445 (4.9) 125/2513 (4.9)
Tertiary education 0/132 (0) 347/3631 (9.6) 347/3763 (9.2)
Hepatitis B positivea 27/132 (20.5) n/a n/a
Hepatitis C positivea 36/132 (27.3) n/a n/a
HIV positivea 8/132 (6) n/a n/a
Alcohol abuse 3/132 (2.3) 0/3631 (0) 3/3763 (0.1)
Smoking status
Smoking 112/132 (84.8) 733/3631 (20.2) 845/3763 (22.5)
Non-smoking 20/132 (15.2) 2898/3631 (79.8) 2918/3763 (77.5)
Cigarettes (per day) 9.9 ± 7.0 1.4 ± 3.9 1.7 ± 4.3
N number, SD standard deviation, PTD preterm delivery, n/a not available
aserologic testing (HBsAg, anti-HCV, anti-HIV), genotype and viral load,
confirmed by PCR analysis
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found for trichomoniasis. Detailed findings on vaginal
screening smears of the 3763 study participants are pre-
sented in Table 2.
Analysis of obstetrical outcomes showed that 19/132
(14.4 %) women in the OMT group and 365/3631 (10 %)
women in the control group experienced PTD. Mean ges-
tational age at delivery was 38.6 ± 2.5 weeks in the OMT
group and 38.7 ± 2.7 weeks in the control group. Mean
birth weight was 2946 ± 550 g and 3245 ± 656 g in the
OMT and control groups, respectively. In the OMT group,
2/19 (10.5 %) of the PTD infants had a birth weight of
500–999 g and 17/19 (89.5 %) had a birth weight of 1500–
2499 g. As shown in Table 3, 21/365 (5.8 %) of the PTD
infants in the control group had a birth weight <500 g,
whereas 44/365 (12 %), 30/365 (8.2 %), 215/365 (58.9 %),
and 55/365 (15.1 %) had a birth weight of 500–999 g,
1000–1499 g, 1500–2499 g, and ≥2500 g, respectively. In
the linear mixed model, birth weight [mean difference,
MD, −165.3 g (95 % confidence interval, CI, −283.6 to
−46.9); p = 0.006] and infant length [MD −0.87 g (95 % CI,
−1.58 to −0.17); p = 0.015] significantly differed between
the study groups. Findings regarding gestational age, Apgar
score, umbilical cord arterial pH, and head circumference
were inconclusive regarding a possible difference (Table 4).
Discussion
In the present study, we found increased odds for asymp-
tomatic vaginal infections and candidiasis in opioid-
dependent women receiving OMT. Our findings suggest
that there is a potential influence of OMT and maternal
opioid dependence on the vaginal flora, which should be
taken into account during antenatal care.
Opioid-dependent women commonly suffer from un-
employment, co-addicted partners, and intimate partner
violence [10, 19]. In contrast to illicit drug abuse, OMT
has a normalising effect on endocrinological and immuno-
logical functioning, which could lead to unexpected preg-
nancy in OMT women with insufficient birth control
Fig. 1 Vaginal flora of the 3763 study participants
Table 2 Vaginal flora of the 3763 study participants (conditional logistic regression model)
Variable OMT group Control group Total Odds ratioa
(95 % CI)
p-value
N (%) N (%) N (%)
Normal or intermediate flora 72/132 (54.5) 2865/3631 (78.9) 2937/3763 (78) 0.49 (0.33 to 0.71) <0.001
Vaginal infection 60/132 (45.5) 766/3631 (21.1) 826/3763 (22) 1.73 (1.19 to 2.53) 0.004
Bacterial vaginosis 24/132 (18.2) 269/3631 (7.4) 293/3763 (7.8) 1.53 (0.93 to 2.53) 0.094
Normal or intermediate flora + Candida spp. 31/132 (23.5) 420/3631 (11.6) 451/3763 (12) 1.92 (1.21 to 3.05) 0.005
Bacterial vaginosis + Candida spp. 3/132 (2.3) 50/3631 (1.4) 53/3763 (1.4) 1.71 (0.47 to 6.24) 0.42
Trichomonas vaginalisb 2/132 (1.5) 27/3631 (0.7) 29/3763 (0.8) 1.34 (0.28 to 6.3) 0.712
Involvement of Candida spp. 36/132 (27.3) 472/3631 (12.9) 508/3763 (13.5) 2.11 (1.36 to 3.27) <0.001
N number, CI confidence interval
acontrol group = reference
bincl. 2 cases with T. vaginalis + Candida in each group
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measures [20]. With regard to the socioeconomic situ-
ation, promiscuous behaviour might foster health prob-
lems including infectious diseases of the lower genital
tract. Curry et al. [21] reported that maternal physical and
sexual abuse, which is likely associated with substance
abuse and the chaotic lifestyles of addicted mothers, was
related to poor obstetric histories. Our study confirmed
the low socioeconomic and educational status of OMT
women, who were young and often tobacco dependent.
Knowing that women with OMT are more likely suffer-
ing from socioeconomic deprivation and experiencing
adverse pregnancy outcomes, one might postulate a poten-
tial cumulative effect in cases of vaginal infection. We
found the rate of Candida involvement to be significantly
higher in the screening smears of OMT women than in
those of the control group. Independent from other poten-
tially unknown confounders, we found that, in our popula-
tion, asymptomatic vaginal infections, and candidiasis in
particular, were common findings among pregnant women
with OMT. Rates of BV and T. vaginalis were also higher
in the OMTgroup, but the differences were not statistically
significant (Fig. 1). Reported candidiasis rates of 10–15 %
Table 3 Obstetrical outcomes of the 3763 study participants (descriptive statistics)
Variable OMT group Control group Total
N (%) N (%) N (%)
Pregnancy outcome Live birth 131/132 (99.2) 3614/3631 (99.5) 3745/3763 (99.5)
Stillbirth 1/132 (0.8) 17/3631 (0.5) 18/3763 (0.5)
Prematurity Preterm delivery 19/132 (14.4) 365/3631 (10) 384/3763 (10.2)
No preterm delivery 113/132 (85.6) 3266/3631 (90) 3379/3763 (89.8)
Mode of delivery Vaginal deliverya 68/132 (51.5) 1939/3631 (53.4) 2007/3763 (53.3)
Caesarean section 53/132 (40.2) 1510/3631 (41.6) 1563/3763 (41.5)
Instrumental delivery 11/132 (8.3) 182/3631 (5) 193/3763 (5.1)
Gestational week at delivery <23w 0d 0/132 (0) 30/3631 (0.8) 30/3763 (0.8)
23w 0d–27w 6d 2/132 (1.5) 38/3631 (1) 40/3763 (1.1)
28w 0d–31w 6d 2/132 (1.5) 37/3631 (1) 39/3763 (1)
32w 0d–36w 6d 15/132 (11.4) 260/3631 (7.2) 275/3763 (7.3)
≥37w 0d 113/132 (85.6) 3266/3631 (90) 3379/3763 (89.8)
Birth weightb <500 g 0/132 (0) 21/3631 (0.6) 21/3763 (0.6)
500–999 g 2/132 (1.5) 44/3631 (1.2) 46/3763 (1.2)
1000–1499 g 0/132 (0) 30/3631 (0.8) 30/3763 (0.8)
1500–2499 g 18/132 (13.6) 215/3631 (5.9) 233/3763 (6.2)
≥2500 g 112/132 (84.9) 3317/3631 (91.4) 3429/3763 (91.1)
N number
aincl. vaginal breech delivery
bno birth weight available for 4 infants (0.1 %) of the control group
Table 4 Obstetrical outcomes of the 3763 study participants (linear mixed model)
Variable OMT group Control group Total Mean differencea
(95 % CI)
p-value
Mean ± SD Mean ± SD Mean ± SD
Birth weight (grams) 2946 ± 550 3245 ± 656 3234 ± 655 −165.3 (−283.6 to −46.9) 0.006
Gestational age (weeks) 38.6 ± 2.5 38.7 ± 2.7 38.7 ± 2.7 −0.05 (−0.45 to 0.54) 0.849
Apgar score
Apgar at 1 minute 8.5 ± 1.2 8.6 ± 1.1 8.6 ± 1.1 −0.03 (−0.24 to 0.17) 0.743
Apgar at 5 minutes 9.5 ± 1.3 9.6 ± 1.1 9.6 ± 1.1 −0.12 (−0.32 to 0.09) 0.264
Apgar at 10 minutes 9.7 ± 0.9 9.7 ± 1.1 9.7 ± 1.1 −0.04 (−0.23 to 0.16) 0.721
Umbilical cord arterial pH (units) 7.27 ± 0.07 7.27 ± 0.08 7.27 ± 0.08 −0.001 (−0.01 to 0.01) 0.854
Head circumference (cm) 33.6 ± 1.8 34.3 ± 2.1 34.3 ± 2.1 −0.38 (−0.77 to 0.01) 0.054
Length (cm) 49.2 ± 3.0 50.7 ± 3.8 50.7 ± 3.8 −0.87 (−1.58 to −0.17) 0.015
SD standard deviation, CI confidence interval, cm centimetres
acontrol group = reference
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at early gestation are comparable to the prevalence ob-
served in our control group (12.9 %), but not to that in the
OMT group (27.3 %) [22–24]. According to our previously
published data, there is an association between recurrent
candidiasis and PTD, but not between one-time candidiasis
and PTD [25]. This finding could be relevant, since
post-treatment re-colonization rates with Candida spp.
are typically high, with rates of up to 50 % within
1 month after completing a short-term antimycotic
therapy [26]. In addition, certain anaerobe microorgan-
isms, which are recognized to be associated with BV,
PTD and stillbirth, could be part of the vaginal flora,
although they are uncultivable and not detectable on
Gram-stains [27, 28]. Culture-independent molecular-based
techniques could have provided detailed information about
the composition of the vaginal flora, probably indicating a
far greater diversity of microorganisms, and thereby enhan-
cing the existing knowledge from Gram-stain and culture-
dependent techniques [29].
Previous studies reported that women receiving OMT
during pregnancy are at risk for PTD, low birth weight,
and small head circumference [30, 31]. Our study detected
a 4.4 % increase in PTD within the OMT group, which
was, however, not significant with regard to the mean ges-
tational age. Peles et al. [32] reported that the best obstet-
rical outcomes in opioid-maintained women, defined by
gestational age and birth weight, were achieved by longer
duration of OMT and substance abstinence, which em-
phasises the importance of OMT stabilisation before and
during pregnancy. Moreover, co-medication and polydrug
abuse might be associated with reduced foetal growth and
adverse outcomes [33, 34]. Dryden et al. [35] reported that
23 % of the infants born to OMT mothers weighed less
than the 9th percentile at delivery. In our study, we found
indicators for impaired foetal growth, such as low birth
weight and short length, in infants of opioid-maintained
mothers. Because our groups were matched for maternal
characteristics, our results are consistent with those of
Mactier et al. [30], who postulated that reduced foetal
growth cannot be fully explained by maternal tobacco
abuse, age, or parity.
From a clinical point of view, our findings indicate that
there is a need for the implementation of routine screen-
ing programmes to prevent vaginal infections in OMT
women. These women constitute a select patient cohort
facing high-risk pregnancies and a special need for early
pregnancy care [36]. Cases of women first presenting for
care at delivery should certainly be prevented, since the
absence of prenatal care allows for an accumulation of risk
factors, which in turn increases PTD risk and subsequent
costs to society. Comprehensive care for the prevention of
PTD should be individualised for every pregnant women.
Screening programmes for the prevention of vaginal infec-
tions should become part of international guidelines for
the prenatal care of OMT women. Although their part-
ners might not obligatorily be screened, the increased risk
for human immunodeficiency virus (HIV) infection and
hepatitis should also be considered.
To the best of our knowledge, this paper is the first to
evaluate the vaginal flora of pregnant women with
OMT. Beyond the aim of our study, which was to evaluate
their vaginal flora, we considered it essential to report our
obstetrical outcomes. Indeed, our study has several limita-
tions, including the retrospective design, the case-control
setting, and the lack of patient characteristics in the con-
trol group. We are aware that characteristics might differ
between opioid-dependent and non-opioid-dependent
women. Although we matched cases and controls for po-
tentially confounding factors, we were unable to adjust for
HIV infection and hepatitis. There might be an increased
prevalence of these infections among women with an ab-
normal vaginal flora, but it remains unclear whether this
difference is related to the infection, the socioeconomic
deprivation, the immunodeficiency, or to other, unknown
factors [37, 38]. Moreover, the increased susceptibility for
vaginal infections in OMT women might also be induced
by a frequent change of sexual partners, high sexual activ-
ity, underlying diseases, or co-abuse of other drugs that
we were unable to adjust for [39]. Finally, it remains un-
clear to what extent the choice and dosage of OMT had
an effect on the outcomes of our study.
Conclusion
In conclusion, our data demonstrate that pregnant women
with OMT are at risk for asymptomatic vaginal infections
at early gestation. In particular, Candida spp. is more fre-
quently involved in vaginal screening smears of women
with OMT, compared to those of the overall pregnant co-
hort. Considering the known effect of vaginal infections on
obstetrical outcomes, our findings indicate the need for a
multidisciplinary approach in the care of pregnant opioid-
dependent, opioid-maintained women, including compre-
hensive screening and treatment for vaginal infections, in
order to potentially prevent the accumulation of risk fac-
tors for adverse perinatal outcomes and PTD. To confirm
our findings, prospective studies are warranted that include
the evaluation of the vaginal flora by culture or PCR.
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